Northeast Florida Medicine
Vol. 66, No. 2 2015
5
VOLUME 66, NUMBER 2
Pediatric Oncology
Summer 2015
EDITOR IN CHIEF
Sunil Joshi, MD
MANAGING EDITOR
Kristy Wolski
ASSOCIATE EDITORS
Ruple Galani, MD (Vice Chair)
James Altomare, MD
Mark Fleisher, MD
Ali Kasraeian, MD
Joseph Sabato, Jr., MD
James St. George, MD
EXECUTIVE DIRECTOR
Bryan Campbell
DCMS FOUNDATION
BOARD OF DIRECTORS
President: Todd Sack, MD
Secretary: Allen Seals, MD
Treasurer: Malcolm Foster, MD
At Large Seat 1: Ruple Galani, MD
At Large Seat 2: Eli Lerner, MD
2015 FOUNDATION DONORS
Kevin M. McAuliffe, MD
William P. Bosworth, DO
William P. Clarke, MD
Philip P. Gaillard, MD
Larry S. Garsha, MD
Jack L. Greider, Jr., MD
Russell D. Metz, MD
Eli Lerner, MD
Duke H. Scott, MD
W. Cannon Simpson, MD
N. H. Tucker, III, MD
William R. Wainwright, MD
MBB Radiology
C
ontents
Summer 2015
Please note: Editorial and contents of this magazine reflect the records of the Duval County Medical Society (DCMS). The DCMS has done their best to provide useful and accurate information, but please
take into account that some information does change. E&M Consulting, Inc., publishers and the DCMS take no responsibility for the accuracy of the information printed, inadvertent omissions, printing
errors, nor do they endorse products and services. We take no responsibility regarding representations or warranties concerning the content of advertisements of products/services for a particular use, including
all information, graphics, copyrighted materials, and assertions included in the advertisements. The reader is advised to independently check all information before basing decisions on such information.
Summer CME
Departments
Wilms Tumor
Outcomes at a Single
Institution and Review
of Current Management
Recommendations
Corey Hobbs, MD and
Michael Olson, MD, PhD
Wilms tumor, or nephroblastoma, is
the most common primary renal tumor
of children, with about 500 cases per
year in the United States. Treatment is
individualized by tumor histology, stage,
and a variety of biologic factors that help
determine a patient’s risk strata, and
may include surgery, chemotherapy, and
radiation therapy. The overall survival rates
in Wilms, treated by current techniques,
is excellent—approaching 90 percent.
Retrospective review of patients treated for
Wilms tumors at Nemours and Wolfson
Children’s Hospital in Jacksonville, Florida
between 1994 and 2012, with a median of
11 years of follow-up, shows a progression
free survival of 89 percent and overall
survival of 98 percent to date, with one
patient deceased and two patients of the 64
patient cohort with active disease.
39
Features
Cynthia Anderson, MD
Guest Editor
By Eric Sandler, MD and Paul Pitel, MD
By Julie A. Bradley, MD, Ronny Rotondo, MD,
Daniel Indelicato, MD
By Cynthia Anderson, MD
By Daniel K. Robie, MD, FACS
By Scott M. Bradfield, MD
